my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
11-23-2006: UCB announced that the EU Commission has cleared the proposed take-over of SCHWARZ PHARMA by UCB. As announced on November 10, 2006, the U.S. Federal Trade Commission (FTC) has allowed the waiting period to expire without expressing any concerns. Therefore, the take-over of SCHWARZ PHARMA by UCB can be pursued both from a European and U.S. antitrust perspective.
UCB announced the commencement of the acceptance period for the take-over of SCHWARZ PHARMA which is from November 10, 2006 until December 8, 2006, 24:00 hours (CET). On November 20, 2006, the Executive Board and Supervisory Board of the SCHWARZ PHARMA AG recommended acceptance of the offer by UCB to the shareholders of SCHWARZ PHARMA AG.
Watchlist
This is where you can add this news to your personal favourites
Successful takevoer of Schwarz Pharma by UCB
UCB announces that it has received tenders amounting to 87.62% of the total outstanding share capital of SCHWARZ PHARMA AG (or 86.80% of the fully diluted share capital, including treasury shares) during its tender offer for SCHWARZ PHARMA which closed on December 28, 2006 at midnight. Shar ... more
New CEO of SCHWARZ PHARMA joins executive commitee of UCB
UCB appointed Detlef Thielgen, SCHWARZ PHARMA's new Chief Executive Officer, to UCB's Executive Committee effective January 1, 2007. In his career with SCHWARZ PHARMA AG, Detlef Thielgen has held several positions in finance and controlling, including Chief Financial Officer in the USA (19 ... more
Significant acceptances by SCHWARZ shareholders for UCB tender offer
The final total of acceptances received by midnight on Friday December 8 will be available on Thursday December 14, 2006. Acceptances already counted show UCB has received tenders in excess of 76% of the fully diluted share capital of SCHWARZ PHARMA. As is required in such a transaction in ... more
UCB transfers UK-based medicinal chemistry program to BioFocus DPI
Galapagos NV announced that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB's medicinal chemistry programs. The total contract value for Galapagos could potentially exceed EUR4 M. Additionally ... more
Pierre Fabre acquires Over-The-Counter Business of UCB in France, Benelux, Switzerland and Greece
Pierre Fabre and UCB jointly announce that Pierre Fabre has acquired the OTC business of UCB in France, Benelux, Switzerland and Greece. The acquisition involves certain mature products with strong brand names (a.o. Carbolevure, Revitalose, Balsoclase, Toclase), representing sales of approx ... more
Successful takevoer of Schwarz Pharma by UCB
UCB announces that it has received tenders amounting to 87.62% of the total outstanding share capital of SCHWARZ PHARMA AG (or 86.80% of the fully diluted share capital, including treasury shares) during its tender offer for SCHWARZ PHARMA which closed on December 28, 2006 at midnight. Shar ... more
Photonics industry commits to more than 5 billion Euros investment in Europe
Photonics21 has announced its commitment to a proposed Public Private Partnership (PPP) with the European Commission in research and innovation in photonics. The proposal represents a total investment of 7 Billion Euros of which 5.6 Billion will be provided by the private sector and 1.4 Bil ... more
European Commission fines Arkema for past anti-trust practices in the heat stabilizer market
Arkema notes the European Commission’s decision relating to past anti-trust practices in the heat stabilizer* market, and confirms that this fine will have no impact on its results. The European Commission issued a total fine of 28.6 million euros to Arkema France and its former parent com ... more
AkzoNobel fined following heat stabilizers investigation
AkzoNobel has confirmed that a fine of up to €40.6 million has been imposed by the European Commission following an investigation into price-fixing involving the company's former Tin Stabilizers (1987-2000) and Esbo/Esters (1991-2000) businesses. These businesses were divested in 2007. The ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
